Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

DOACs May Have Advantage Over VKAs After TAVI, Study Hints

News Daily News

DOACs May Have Advantage Over VKAs After TAVI, Study Hints

July 14, 2021

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

News

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Yael L. Maxwell

July 13, 2021

OMT Boosts Survival in Revascularized Patients at 10 Years

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

May 16, 2021

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

News Daily News

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

May 14, 2021

May 2021 News Roundup

News Opinion CV Team Dispatch

May 2021 News Roundup

May 01, 2021

EHRA Updates Its Popular ‘Practical’ NOAC Guide

News Conference News EHRA 2021

EHRA Updates Its Popular ‘Practical’ NOAC Guide

April 29, 2021

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

Primary PCI Underused but Just as Effective in Cancer Patients With STEMI

News Daily News

Primary PCI Underused but Just as Effective in Cancer Patients With STEMI

Michael O'Riordan

February 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.